SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories - Quaterly Results

15 May 2025 Evaluate
The sales slipped to Rs. 3283.60 millions for the March 2025 quarter as against Rs. 3850.10 millions during the year-ago period.Net profit of the cmpany stood at Rs. 277.34 millions for the quarter ended March 2025 a decline of -58.98% from Rs. 676.06 millions  in the same quarter last year.Operating Profit reported a sharp decline to 582.18 millions from 1121.51 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 3283.60 3850.10 -14.71 14768.37 15585.80 -5.24 14768.37 15585.80 -5.24
Other Income 74.64 53.57 39.33 205.09 125.44 63.50 205.09 125.44 63.50
PBIDT 582.18 1121.51 -48.09 3428.08 4744.65 -27.75 3428.08 4744.65 -27.75
Interest 23.46 36.09 -35.00 82.96 139.97 -40.73 82.96 139.97 -40.73
PBDT 558.72 1085.42 -48.52 4109.16 4604.68 -10.76 4109.16 4604.68 -10.76
Depreciation 168.90 164.62 2.60 655.42 596.99 9.79 655.42 596.99 9.79
PBT 389.82 920.80 -57.67 3453.74 4007.69 -13.82 3453.74 4007.69 -13.82
TAX 112.48 244.74 -54.04 859.48 1011.73 -15.05 859.48 1011.73 -15.05
Deferred Tax 53.11 25.50 108.27 122.95 15.87 674.73 122.95 15.87 674.73
PAT 277.34 676.06 -58.98 2594.26 2995.96 -13.41 2594.26 2995.96 -13.41
Equity 129.01 129.01 0.00 129.01 129.01 0.00 129.01 129.01 0.00
PBIDTM(%) 17.73 29.13 -39.13 23.21 30.44 -23.75 23.21 30.44 -23.75

Neuland Laboratories Share Price

14775.00 -156.45 (-1.05%)
22-Apr-2026 10:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1660.45
Dr. Reddys Lab 1215.40
Cipla 1226.30
Zydus Lifesciences 928.40
Lupin 2300.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×